SignalFDA/Bio

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

Phase 3 data shows meaningful benefits beyond growth in children within 52 weeks.

What changed

Phase 3 data shows meaningful benefits beyond growth in children within 52 weeks.

Why it matters

Phase 3 data shows meaningful benefits beyond growth in children within 52 weeks. — impact context not separately stored; see What changed.

Sources